Novavax (NVAX) Q4 2025 earnings review
A Successful Pivot, But a Deep 'Transition Gap' Looms for 2026
Novavax capped off a transformational 2025 by successfully pivoting from a struggling commercial vaccine maker to a lean, platform-licensing R&D engine. Q4 results look excellent on the surface: Revenue jumped 67% YoY to $147M, and net income swung to an $18M profit (vs. an $81M loss a year ago), largely driven by $98M in Sanofi collaboration revenues and severe cost cuts. However, beneath the surface, a massive revenue cliff awaits. Stripping away 2025's one-time APA settlements and initial partner milestones, 2026 Adjusted Total Revenue guidance is set at a sobering $230-$270M. To survive this multi-year transition until Sanofi royalties and potential pipeline milestones kick in, management is leaning heavily into Matrix-M adjuvant licensing—highlighted by a new $500M+ Pfizer deal—and aggressively slashing operating expenses.
🐂 Bull Case
The January 2026 Pfizer deal ($30M upfront, up to $500M in milestones + royalties) for two infectious disease targets proves Matrix-M's standalone value. Combined with the Sanofi partnership and Malaria vaccine success (30M doses), the adjuvant is becoming a diversified revenue engine.
Management executed a ruthless but necessary cost-cutting campaign. Q4 SG&A collapsed 56% YoY. They beat 2025 OpEx reduction goals and lowered 2027 R&D/SG&A targets to $225M, establishing a realistic survival baseline.
🐻 Bear Case
With the $603M Q1 APA settlement and massive initial Sanofi milestones in the rearview mirror, 2026 is a financial valley. A $250M midpoint revenue target means the company will burn cash while waiting for Sanofi to ramp up commercialization.
The target to achieve non-GAAP profitability has been delayed from 2027 to 2028, reflecting Novavax's complete dependence on third-party (Sanofi) clinical execution timelines for the COVID-Influenza Combination (CIC) program.
⚖️ Verdict: ⚪
Neutral. The strategic pivot to a partnership model was executed flawlessly, saving the company from bankruptcy. However, the sheer size of the 2026 revenue drop and the delayed 2028 profitability target highlight that Novavax is now essentially a call option on Sanofi's commercial success and Matrix-M's broader adoption.
Key Themes
Matrix-M Licensing Becomes the Core Growth Engine
The narrative has officially shifted: Novavax is now a Matrix-M adjuvant licensing company. The newly announced January 2026 Pfizer agreement grants a non-exclusive license for two infectious disease targets, netting $30M upfront with $500M in potential milestones plus royalties. Combined with multiple new Material Transfer Agreements (MTAs) signed in Q4 2025/Q1 2026 across large pharma and oncology, Matrix-M is being heavily monetized to bridge the revenue gap.
Sanofi Partnership Execution De-Risks Pipeline
The Sanofi collaboration continues to bear fruit. Novavax recognized $98M from Sanofi in Q4, capping off $225M in milestones earned for FY25 upon the transfer of EU and U.S. marketing authorizations. Crucially, Sanofi reported positive Phase 1/2 data for its influenza-COVID-19 combination program, which carries up to $350M in future development and launch milestones for Novavax.
Relentless Operational Cost Reductions
Management has successfully dismantled its legacy commercial infrastructure. Q4 SG&A expenses dropped 56% YoY to $34M, and R&D fell 27% to $76M. The company exceeded its 2025 cost reduction targets and lowered the floor further: targeting combined R&D/SG&A of $225M in 2027 and <=$200M by 2028. This discipline is the only way the company survives the upcoming revenue trough.
Nuvaxovid Direct Commercial Sales Have Collapsed
The transition away from commercial operations is reflected brutally in the product sales data. Q4 Nuvaxovid sales plummeted 60% YoY to just $20M (down from $50M). With Sanofi taking the commercial lead for the 2026-2027 season, Novavax is entirely reliant on its partner's ability to drive volume in a broadly contracting global COVID-19 vaccine market.
Profitability Timeline Extended to 2028
As telegraphed in the Q3 call, the target for non-GAAP profitability has been pushed from 'as early as 2027' to 2028. This delay explicitly highlights a severe vulnerability: Novavax is a passenger to Sanofi's clinical timelines. A 6-12 month delay in Sanofi's COVID-Influenza Combination (CIC) program directly impacts Novavax's cash flow, forcing them to rely on baseline cost-cutting to survive the wait.
Government Funding and Pandemic Preparedness Tailwinds
As noted in prior quarters, the shifting U.S. government (BARDA) landscape away from exclusive mRNA focus presents a macro tailwind for Novavax's protein-based platform. The ongoing advancement of the H5N1 pandemic influenza candidate (which showed protective immunity after a single dose in nonhuman primates) aligns well with global pandemic preparedness initiatives.
Other KPIs
Down from $938M at the end of 2024. While cash burn is stabilizing relative to the company's past, the massive drop in 2026 expected revenue necessitates a strong buffer. In February 2026, Novavax wisely secured a $330M credit facility (with an initial $50M draw) to guarantee non-dilutive liquidity through the transition period.
Up 65% YoY from $682M in 2024. However, this figure is highly deceptive regarding run-rate business. It includes $625M in Nuvaxovid product sales, the vast majority of which were tied to non-cash settlements of canceled Advance Purchase Agreements (APAs) recognized entirely in Q1 2025.
Guidance
Reversing. A dramatic drop from the $1.1B reported in FY25, reflecting the exhaustion of one-time APA settlements and the transition of commercial leadership to Sanofi. This guidance completely excludes Sanofi Supply Sales, Sanofi Royalties, and Sanofi CIC milestones, meaning any success Sanofi has will act as pure upside to this baseline.
Accelerating cost reductions. Down roughly 20% from the $408M non-GAAP figure posted in FY25. The midpoint of $325M shows management is on track with its multi-year restructuring plan to reach a $200M or below run-rate by 2028.
Decelerating from FY25's inflated base, but represents the new core business. Includes $70-$80M in R&D reimbursement from Sanofi, $50-$60M from other partners (including the new $30M Pfizer upfront payment), and $35M in non-cash amortization.
Key Questions
Pfizer Matrix-M Targets
The Pfizer agreement covers two specific infectious disease targets. Given Pfizer's existing mRNA portfolio, what specific gaps or modalities is Matrix-M being brought in to solve, and what is the expected timeline to clinical entry?
Bridging the 2026 Cash Trough
With 2026 Adjusted Revenue guided down to $250M at the midpoint, and OPEX guided to ~$325M, operational cash burn is imminent. Is the newly announced $330M credit facility expected to fully cover the gap until Sanofi royalty streams mature in 2027/2028?
Sanofi CIC Program Outlook
Following Sanofi's positive Phase 1/2 data for the influenza-COVID-19 combination program, what are the specific gating factors regulators are requiring for Phase 3 progression, and how does this impact the timing of the $350M in potential milestones?